Janssen
Janssen outlines pipeline ambitions
May 24, 2013Research and Development, Sales and Marketing Janssen, Johnson and Johnson, pipeline
Janssen has outlined plans to submit ‘more than ten’ new product filings worldwide in the next four years, along with …
South Korea eyeing criminal charges over J&J plant failures
May 17, 2013Manufacturing and Production J&J, JJ, Janssen, Korea, MFDS
The chief executive of Johnson & Johnson’s South Korean subsidiary could be facing criminal charges over quality lapses at a …
Janssen submits diabetes combination
March 12, 2013Sales and Marketing Janssen, diabetes
Janssen has submitted a combination of its investigational diabetes drug canagliflozin with immediate-release metformin to the European Medicines Agency.The manufacturer, …
Abbott seeks leukemia test
February 25, 2013Sales and Marketing AbbVie, Abbott, Janssen
Abbott is to team up with Janssen Biotech and biopharma firm Pharmacyclics to seek a diagnostic test for leukemia patients. …
Janssen launches dementia prize
February 15, 2013Sales and Marketing Hunt, Janssen, NHS, dementia
Janssen has joined forces with the NHS to launch a scheme to financially reward solutions which can help the lives …
Bayer/Janssen seek Xa inhibitor antidote
February 6, 2013Research and Development, Sales and Marketing Bayer, Janssen, PRT4445, Xarelto
Bayer HealthCare and Janssen Pharmaceuticals have signed a deal with Portola Pharmaceuticals to evaluate the safety of an investigational antidote …
J&J seeks end to Doxil shortage as Ben Venue signs consent decree
January 28, 2013Manufacturing and Production Ben Venue, Boehringer, Caelyx, Doxil, J&J, JJ, Janssen
Johnson & Johnson says it has taken steps to establish new supplies of its cancer drug Doxil/Caelyx, which remains in …
Zytiga extended in EU
January 15, 2013Sales and Marketing EU, J&J, JJ, Janssen, Zytiga
Janssen is celebrating the European Commission’s decision to extend the licence for its prostate cancer treatment Zytiga. The once-daily pill …
Janssen’s diabetes drug Invokana recommended
January 11, 2013Sales and Marketing Janssen, SGLT2, canagliflozin, diabetes, invokana
An FDA advisory committee has recommended Janssen’s new diabetes treatment canagliflozin for approval. To be marketed under the name Invokana, …
FDA vote on J&J diabetes drug
January 10, 2013Sales and Marketing EU, FDA, J&J, JJ, Janssen, canagliflozin
Key advisers to the FDA are meeting today to decide whether Janssen Pharmaceuticals’ type II diabetes drug canagliflozin is safe …
Alzheimer’s drug lowers mortality
December 7, 2012Sales and Marketing Alzheimer's, Janssen, Razadyne, Roche, lilly
A study of Janssen Pharmaceuticals’ Razadyne suggests that the Alzheimer’s drug helped patients stay alive longer and slowed their cognitive …
Janssen eases HIV patent burden
December 3, 2012Sales and Marketing AIDS, Janssen, Prezista, darunavir
In a move which should appeal to public health campaigners, Janssen has declared that it will not enforce patents for …
Janssen and GSK in hep C tie-ups
November 8, 2012Research and Development, Sales and Marketing GSK, Janssen, Vertex, hep C
Janssen and GlaxoSmithKline are to conduct separate Phase II studies with Vertex Pharmaceuticals to test an investigational all-oral regimen to …
Two hepatitis C drugs win Prix Galien
September 28, 2012Medical Communications, Sales and Marketing Incivo, Janssen, MSD, Victrelis, prix galien
Two new hepatitis C drugs have been given the 2012 UK Prix Galien innovative product award as joint winners in …
Pfizer pays $60m in bribery cases
August 8, 2012Sales and Marketing DoJ, FDA, GSK, Janssen, Pfizer, Wyeth, bribery
Pfizer has been fined $60 million for making improper payments to doctors in Europe, Asia and the Middle East. The …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
